Nootropic drugs in the combination therapy of chronic alcoholism

DOI: https://doi.org/10.29296/25877305-2018-11-04
Download full text PDF
Issue: 
11
Year: 
2018

T. Potupchik(1), Candidate of Medical Sciences; T. Lopatina(1); V. Lopatin(2) 1-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University 2-Krasnoyarsk Territorial Narcology Dispensary One, Krasnoyarsk

The paper gives data on the use of nootropic drugs that may be used in the combination therapy of chronic alcoholism.
Keywords: 
drug addiction
ethanol
alcoholism
withdrawal syndrome
cognitive impairment
nootropics

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bardenshtejn L.M., Gerasimov N.P., Mozhginskij Ju.B. i dr. Alkogolizm, narkomanii, toksikomanii. Ucheb. posobie / M.: GEOTAR-Media, 2007; 55 s.
  2. Andrianova E.D., Damulin I.V., Sivolap Ju.P. Kognitivnye rasstrojstva pri alkogolizme // Narkologija. – 2013; 12 (6): 79–85.
  3. Ahapkina V.I., Voronina T.A. Spektr farmakologicheskih effektov Fenotropila // Farmateka. – 2005; 13: 12–3.
  4. Ahramejko A.V. Sovremennye aspekty lechenija alkogolizma // Molodoj uchenyj. – 2015; 19: 255–9.
  5. Belenichev I.F., Pavlov S.V., Sokolik E.P. i dr. Novye vozmozhnosti lechenija alkogol'noj bolezni. Perspektivy primenenija Tserebrokurina // Mezhdunar. nevrol. zhurn. – 2009; 1: 105–19.
  6. Vostrikov V.V. Mesto piratsetama v sovremennoj prakticheskoj meditsine // Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. – 2017; 15 (1): 14–25.
  7. Vostrikov V.V., Tsygan V.N., Nurmanbetova F.N. i dr. Korteksin v terapii postabstinentnogo sindroma u bol'nyh alkogolizmom. Lechaschij vrach [Elektronnyj resurs]. Rezhim dostupa: https://www.lvrach.ru/2005/06/4532712/
  8. Gorina A.S., Kolesnichenko L.S. Aminokisloty syvorotki krovi i mochi u detej s sindromom Aspergera // Sib. med. zhurn. – 2011; 7: 69–73.
  9. Gosudarstvennyj reestr lekarstvennyh sredstv [Elektronnyj resurs]. Rezhim dostupa: http://www.grls.rosminzdrav.ru/Default.aspx
  10. Gusev E.I., Skvortsova V.I. Ishemija golovnogo mozga / M.: Meditsina, 2001; 328 s.
  11. Eryshev O.F., Rybakova T.G., Shabanov P.D. Alkogol'naja zavisimost': Formirovanie. Techenie. Protivoretsidivnaja terapija / SPb: ELBI-SPb, 2002; 189 s.
  12. Zhernova E.V., Losenkov I.S., Vjalova N.M. i dr. Protektivnyj effekt korteksina v uslovijah indutsirovannogo okislitel'nogo stressa i pod vlijaniem etanola na modeli limfotsitov perifericheskoj krovizdorovyh lits // Fundamental'nye issledovanija. – 2012; 7 (2): 314–8.
  13. Zozulja I.S., Martynjuk V.Ju., Majstruk O.A. Nejroprotektory, nootropy, nejrometabolity v intensivnoj terapii porazhenij nervnoj sistemy / K., 2005; 130 s.
  14. Ivanets N.N., Vinnikova M.A., Mohnachev S.O. i dr. Terapevticheskaja effektivnost' i bezopasnost' ispol'zovanija fenotropila u bol'nyh s zavisimost'ju ot alkogolja // Voprosy narkologii. – 2008; 4: 16–32.
  15. Kamchatnov P.R., Vorob'eva O.V., Rachin A.P. Korrektsija emotsional'nyh i kognitivnyh narushenij u patsientov s hronicheskoj ishemiej golovnogo mozga // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2014; 4: 52–6.
  16. Kulagin A.V. Nauchnye osnovy sozdanija sistemy reabilitatsii lits s razlichnymi formami zavisimosti (nikotinovaja, alkogol'naja, narkomanija, toksikomanija) i mediko-ekonomicheskie otsenki ee effektivnosti. Avtoref. dis. ... kand. med. nauk. SPb: B.i., 2005; 21 s.
  17. Lovat' M.L., Vinnikova M.A., Kozyreva N.A. i dr. Vlijanie nootropnogo preparata semaks na povedencheskie priznaki abstinentnogo sindroma i vlechenie k alkogolju u belyh krys, a takzhe otsenka ego klinicheskoj effektivnosti i bezopasnosti u patsientov, stradajuschih alkogol'noj zavisimost'ju // Nejrohimija. – 2008; 25 (1–2): 49–56.
  18. Nadezhdin A.V. Vozrastnye osobennosti narkologicheskih zabolevanij. Rukovodstvo po narkologii. Pod red. N.N. Ivantsa / M.: Medpraktika-M, 2002; T. 1: s. 408–22.
  19. Petruhin A.S., Pylaeva O.A. Tserebrolizin v pediatricheskoj i nevrologicheskoj praktike // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2014; 1–2: 75–80.
  20. Potupchik T.V., Veselova O.F., Evert L.S. Farmakodinamicheskie aspekty primenenija nootropnyh sredstv pri kognitivnyh narushenijah // Farmateka. – 2014; 13: 90–5.
  21. Potupchik T.V., Veselova O.F., Evert L.S. i dr. Spektr farmakologicheskih effektov glitsina // Vrach. – 2015; 12: 14–7.
  22. Razvodovskij Ju.E. Mediko-sotsial'nye aspekty alkogolizma / Grodno, 2005; 128 s.
  23. Rodinskij A.G., Demchenko T.V, Romanenko L.A. Mediatornye i metabolicheskie svojstva GAMK v nervnoj sisteme (obzor literatury) // Vestnik problem biologii i meditsiny. – 2014; 2: 38–44.
  24. Rumjantseva S.A., Fedin A.I., Sohova O.N. Antioksidantnaja terapija ishemicheskih porazhenij golovnogo mozga // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2011; 4: 28–31.
  25. Selin A.A., Lobysheva N V., Vorontsova O.N. Mehanizm dejstvija glitsina kak protektora narushenija energetiki tkanej mozga v uslovijah gipoksii // Bjull. eksperim. biologii i meditsiny. – 2012; 1: 52–5.
  26. Sivolap Ju.P. Zloupotreblenie alkogolem i farmakoterapija alkogolizma // Nevrologija, nejropsihiatrija, psihosomatika. – 2014; 6 (3): 4–9.
  27. Starchina Ju.A. Primenenie Aktovegina v nevrologii // Farmakoterapija. – 2010; 63–7.
  28. Starchina Ju.A. Nejroprotektivnaja terapija v klinicheskoj praktike // Farmateka. – 2012; 14: 65–9.
  29. Strahov V.V., Popova A.A., Fedorov V.N. Rezul'taty issledovanija nejroprotektornoj effektivnosti preparata «Semaks» // Oftal'mol. vedomosti. – 2014; 7 (4): 43–51.
  30. Syropjatov O.G., Dzeruzhinskaja N.A. Patogenez i biologicheskoe lechenie alkogolizma (Posobie dlja vrachej) / UVMA, 2000; 46 s.
  31. Umarova H.Ja., Chugunov A.V., Kazakov A.Ju. Primenenie Biotredina v praktike nevrologa // Nevrol. i psihiat. – 2014; 94 (6): 49–52.
  32. Shavlovskaja O.A. Alkogol'nye porazhenija nervnoj sistemy. Nejroprotektivnaja terapija // Effekt. farmakoter. – 2014; 17: 16–24.
  33. Shavlovskaja O.A. Primenenie aktovegina pri nejroprotektivnoj terapii bol'nyh s tserebrovaskuljarnymi zabolevanijami // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2013; 6: 74–6.
  34. Sheshegova E.V., Tjukina E.S., Nartsissov Ja.R. i dr. Biotredin v pediatricheskoj praktike // Vrach. – 2016; 12: 27–30.
  35. Jahno N.N. Kognitivnye rasstrojstva v nevrologicheskoj praktike // Nevrol. zhurn. – 2016; 6: 4–12.
  36. Brann D., Bhat G., Lamar C. et al. Gaseous transmitters and neuroendocrine regulation // Neuroendocrinology. – 1997; 65: 385–95.
  37. Caram-Salas N., Reyes-Garcia G., Medina-Santillán R. et al. Thiamine and cyanocobalamin relieve neuropathic pain in rats: synergy with dexamethasone // Pharmacology. – 2006; 77 (2): 53–62.
  38. Chinchilla A., Lopez-Ibor J., Vega M. et al. CDP-colina en la evolucion de lasfuncionesmentales en el sindrome de abstinenciaalcoholica // Psiquiatria Biologica. – 1995; 2: 171–5.
  39. Sohen B. GABA-transaminase, the liver and infantile autism // Med. Hypotheses. – 2001; 57 (6): 673–4.
  40. Dhar-Mascareno M., Cacramo J. Hypoxia – reoxygenation – induced mitochondrial damage and apoptosis in human endothelial cells // Free Radic. Biol. Med. – 2005; 38 (10): 1548–54.
  41. Kaáuzna-Czaplinska J., Michalska M., Rynkowski J. Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry // Med. Sci. Monit. – 2010; 16 (10): 488–92.
  42. Idrus N., McGough N., Riley E. et al. Administration of memantine during withdrawal mitigates overactivity and spatial learning impairments associated with neonatal alcohol exposure in rats // Alcohol Clin. Exp. Res. – 2014; 38 (2): 529–37.
  43. Krupitsky E., Neznanova O., Masalov D. et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients // Am. J. Psychiatry. – 2007; 164 (3): 519–23.
  44. Machicao F., Muresanu D., Hundsberger H. et al. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action // J. Neurol. Sci. – 2012; 322: 222–7.
  45. Neuropeptide Y. Its multiple effects in the CNS and potential clinical significance // Neurology. – 2009; 72 (11): 1016–20.
  46. Renshaw P., Daniels S., Lundahl L. et al. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report // Psychopharmacology. – 1999; 142: 132–8.
  47. Secades J. Citicoline: pharmacological and clinical review, 2010 update // Rev. Neurol. – 2011; 52 (2): 1–62.
  48. Takei N., Nawa H. mTOR signaling and its roles in normal and abnormal brain development // Front. Mol. Neurosci. – 2014; 7: 28–33.
  49. Yao J., Sun J., Zhao Q. et al. Neuregulin-1/ErbB4 signaling regulates Kv4.2-mediated transient outward K+ current through the Akt/mTOR pathway // Am. J. Physiol. Cell Physiol. – 2013; 305 (2): 197–206.